The global critical care diagnostic (CCD) market size was estimated at USD 837.6 million in 2015. These diagnostic tests deal with the specialized care and diagnosis of life-threatening diseases occurring in patients. The tests are cost-effective and easy-to-use with a rapid and accurate diagnosis. They are used around the world in emergency rooms, operating rooms, and intensive care units (ICU’s).
The emergency room services segment is anticipated to witness the highest growth rate. Approximately 58% get admitted into emergency rooms, whereas nearly 20% of acute-care patients get admitted into ICU’s. An increase in the awareness levels of physicians and patients’ requirements for a high-quality treatment are expected to be the factors that drive the industry growth.
Critical care diagnostics market, by type, 2013 - 2024 (USD Million)
The varying types of technological advancements in the industry are further expected to boost this industry during the forecast period. For example, the i-Stat blood gas analyzer by Abbott combines self-contained cartridges with electrochemical detection and micro fluidic components, providing accurate, and sensitive results. The increasing awareness and demand for cost-efficient, rapid, and accurate diagnostic tests are likely to trigger advancements in the industry. However, high costs of these tests and the scarcity of skilled labor to handle new platforms pose as challenges to the industry growth.
On the basis of type, this industry is categorized into routine and special chemistry, flow cytometry, hematology, immunoproteins, microbial and infectious diseases, coagulation, and others. The immunoproteins segment of this market in terms of value was estimated to account for the largest share in 2015, due to a rise in the demand for rapid and accurate early diagnosis as well as the ability to reduce the recovery time of patients.
The critical care diagnostics segment accounts for 2% to 3% of the in-vitro diagnostic market. As the awareness levels of patients for better healthcare options have improved and physician’s knowledge of target therapy has increased, the demand for these diagnostics has expanded. The growth of the overall market is majorly driven by factors, such as clinical chemistry, flow cytometry tests, and coagulation tests, among others. Moreover, microbiology and infectious tests along with immunoproteins assays are estimated to drive segment growth over the forecast period.
CCD’s are majorly used in hospital ancillary locations, such as emergency rooms, operating rooms, and ICU’s, among others. The growing adoption of telehealth and increasing awareness of advanced diagnostics tools has influenced the growth of the market. The use of emergency rooms in this diagnostics market is expected to drive the segment growth during the forecast period.
The key regions surveyed in the report are North America, Europe, Asia Pacific, Latin America the Middle East, and Africa. In terms of growth rate, the Asia Pacific critical care industry is estimated to account for the highest compounded annual growth rate during the forecast period.
This growth is traceable to the increasing presence of geriatric population, increasing number of intensive care specialized hospitals in India, and improved healthcare infrastructure in many rural areas. In addition, the new health reforms in China by the government expanded the insurance coverage of patients and improved the primary healthcare systems. As of 2015, the North American CCD market was estimated to account for the largest share of the global market, followed by Europe.
The key players influencing this industry include Abbott, Alere, Inc., Beckman-Coulter, and Roche, among others. These companies are majorly engaged in technological advancements, new product development, joint ventures, partnerships, and collaborations to maintain their position in industry. For example, in February 2016, Abbott acquired Alere, which is a healthcare management company also providing point-of-care solution.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.